menu search

NAMS / NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023
NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating robust global demand. Lead asset obicetrapib is set to present top-line data in 2H24, with potential approval by 2025-2026. Obicetrapib is a novel oral LDL-c lowering treatment that can be taken with statins and ezetimibe, which we believe to have a peak sales of ~$2bn. Read More
Posted: Aug 19 2023, 13:10
Author Name: Seeking Alpha
Views: 111557

NAMS News  

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

By Seeking Alpha
October 2, 2023

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial de more_horizontal

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

By GlobeNewsWire
September 20, 2023

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or more_horizontal

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

By Seeking Alpha
August 19, 2023

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating ro more_horizontal

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

By The Motley Fool
June 7, 2023

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the more_horizontal

NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech

By Seeking Alpha
March 13, 2023

NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech

NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharma has a promising pipeline drug called Obicetra more_horizontal


Search within

Pages Search Results: